Involves patient’s own mononuclear cells transformed into ‘cancer-fighting’ Dendritic cells.
Dendritic cells are Immune cells that help in Immune-recognition process, absent in cancer patients.
Denvax is best given in combination with conventional treatment plan like surgery, radiation and chemotherapy.
This Immunotherapy for Cancer Targets only the cancer cells without harming the healthy ones.
The disseminated cancer cells responsible for the recurrence and relapse of cancer in treated patients.
Slows the spread of cancer, prevents relapse and gives quality life to most patients. Book an appointment today to know more about immunotherapy cancer treatment and immunotherapy cost in India.
In cancer, the immune system fails, cells of the immune system fail to recognize the cancer cells. The immune system doesn't see tumors as dangerous or foreign and doesn't mount a strong attack against them. Another reason tumors may not stimulate an immune response is that cancer cells develop ways to escape the immune system.
A dendritic cell is a special type of immune cell that boosts immune responses in our body, by showing antigens on its surface to other cells of the immune system.
Dendritic cells identify cancer cells, process them into bits, and jumpstart the immune response by bringing the cancer cells to the attention of the rest of the immune system.
The activated immune system then circulates throughout the body and destroys cancer cells.
The patient or the attendant is required to contact our office, preferably nearby the patient's location. Patient is then required to send his reports and a short video, explaining or showing his/her current clinical status. The doctor evaluates the patient's clinical condition and may or may not advise Denvax, based on Eligibility Criteria. Patients willing to take Denvax treatment are required to fill and sign Informed Consent Form. The Logistics team then works at collection of blood drawl from patient’s home. They assign a trained technical staff to travel to the patient’s location for blood collection. It takes 8 days to manufacture Denvax. Denvax is then delivered via trained technical staff to the patient's home for administration.
Alternatively, patients living near and around The Denvax Clinics, may visit the Denvax office and get the treatment at The Denvax Clinic.
Dr. Jamal A. Khan and Dr. Sharmin Yaqin are leading cancer Immunotherapists in India, who introduced the concept of customised treatment in cancer, cell-based treatments, and cancer Immunotherapy.
Dr. Sharmin Yaqin, MBBS, MD (Clinical Biochemistry), was pursuing her post- graduate when she developed interest in protein extraction, and their role in cancer behaviour..Read More
Dr Jamal A. Khan, MBBS, MD (Medical Microbiology), was a professor in Indian university, teaching Immunology when he developed interest in the power of immune system..Read More
A 46-year-old male was operated for mediastinal tumor in 2010. It was diagnosed as T-cell lymphoma (Lymphoblastic Lymphoma). He started his treatment with chemotherapy. Each time he had to be admitted for managing the complications of chemotherapy. He was losing weight and appetite and having erosions of mucosal membrane. He required G-CSF injections along with antibiotics and lots of IV fluids to maintain his cell counts and nutrition. He was unable to tolerate 4th dose of chemotherapy when he consulted his oncologist to combine chemotherapy with dendritic cell therapy. During the course of conventional treatment, he received mediastinal radiation also for 4 weeks. The oncologist accepted the protocol and the chemotherapy was combined with DENVAX cell therapy doses that concluded in six months (from November 2010 to April 2011).
With this combined approach he stopped developing the post-chemotherapy complication. The patient suffered no chemo-related adverse effects contrary to the earlier findings. He has improved in performance status and is working in his office without taking a day-off from work. He is having regular follow ups and is free of disease as confirmed by his PET-CT in January 2011.
Ms. ArunaTyagi, a 44-year-old patient of cholangiocarcinoma (gallbladder duct) treated by Dr. Jamal A. Khan by dendritic cell therapy, is cancer-free for the last five years. Ms. Tyagi had primary cancer in common bile duct, pancreas and duodenum. She was operated upon by Whipple's procedure in May 2006 and completed her chemotherapy and radiation, but the success was short lived. After 9 months she developed a swelling in abdominal wall (secondary metastsis). The surgeon took a second chance and she was again operated for abdominal metastasis. She was offered second line chemotherapy by her treating physician but she refused knowing it would not give her long term benefits. She came to know of Dr. Jamal A. Khan, cancer immunotherapist, pioneer of Dendritic cell therapy in India. Dr. Khan MBBS, MD who has treated over a thousand patients till date, discussed the cancer treatment plan with her. She was constantly monitored by serum marker tests and ultrasound exams. Gradually, the DENVAX therapy was given at increasing intervals. In August 2009, she was subjected to PET-CT examination and found to be completely free of disease with no active lesions found.
She continues to receive Denvax Therapy from Dr. Jamal A. Khan and is cancer-free, till date.
Disclaimer: It is the OTPL’s policy never to disclose patient identity. This is an isolated case where we are disclosing the patient's identity. This information is shared in consent with Mrs. ArunaTyagi. It has also been covered in the magazine 'The Week' published from India dated 11 August, 2012.
A 60-year-old female presented with metastatic clear cell carcinoma of kidney in December 2007. Her right kidney was excised and subjected to histopathology examination. It revealed pathological stage TNM- pT3 N1 M1. Her complaints were pain in abdomen and frequent urination. She presented with weight loss and anemia.
She was given the option of DENVAX, dendritic cell-based immunotherapy. She received five doses at monthly interval. In three doses, her complaints began to resolve and was back to her normal self in five doses. Intermittently, she continued to receive DENVAX therapy.
She was again evaluated in March 2011 for routine check up and was further advised to received additional DC therapies. Her reports indicate no active disease. Overall her health is good and she does all her normal activities without any assistance.
She is completing 4 years of her quality life without receiving chemotherapy, monoclonal antibodies or interferons and is maintained on dendritic cell therapy.
An elderly male suffering from cancer of the urinary bladder (Transitional Cell Carcinoma) received Denvax therapy. He developed the disease in 2012 that was surgically removed. Post-surgery he opted for Denvax therapy. The referral came from his daughter who is a leading pathologist in Mumbai. During the first three months of therapy he additionally received BCG infusions into the urinary bladder given by his surgeon. Unfortunately, the disease relapsed in four months and he had to undergo second surgery to clear off the lesion. They were now having options to take chemotherapy although expected success was very little. The surgeon asked them to consider taking out urinary bladder completely but patient refused due to the poor quality of life he would lead. We suggested considering exclusive Dendritic cell therapy as BCG had failed to check the disease before moving to next step. It is known that the BCG treatment creates inflammatory response and serves as bait for immune cells to come and take control of cancer cells. The inflammatory response probably disturbed the T-cell based protection that we were going to get with Dendritic cells. The patient agreed and we gave him another set of six doses of Denvax. He was re-examined and no new growth of tumor was detected. He continues to receive Denvax at three-months interval. It is almost three years of disease-free period now. He plays golf five days-a week and drives his car at the age of 76 years.
A young female consulted me in late 2014. She had a history of HCC (Hepatocellular carcinoma) with Hepatitis B positive status, with resection performed in early 2014. Gradually she progressed with disease. When she came to our clinic she had weakness and lethargy. Her PET-CT indicated disease in the liver and lungs. Her lab parameters were deranged but serum bilirubin was within normal limits. She was put on Denvax, dendritic cell therapy, and within three months of therapy she started showing signs of improvement. Her latest PET-CT done this month has shown complete resolution of the disease. Additionally, her hepatitis B test has become negative. Nothing of this sort has ever been reported in the medical literature.
A dynamic, middle-aged male diagnosed of metastatic RCC (Renal cell carcinoma) and operated in 2012, developed widespread metastasis by 2013. He was treated in one of the leading hospitals in Gurgaon. He was taking monoclonal antibody (mab) designed for RCC but to no avail. He consulted and opted for additional (adjuvant) Dendritic cell therapy. We gave him the first dose in January 2014. The mab was gradually reduced to half and subsequently to quarter of the standard dose. He started gaining weight and cleared off of all his lesions in the body. His PET CT indicated complete resolution of the disease. He is on dendritic cell therapy maintenance therapy at monthly intervals. He travels widely not only between cities but countries due to his professional commitments. He can afford that as his health is perfectly normal and has no complaints of whatsoever type he used to have earlier. His lab parameters are also normal. He is evaluated in August 2015
A 58-year-old lady was diagnosed of cancer ovary in June 2004. Her CA 125 antigen marker was positive and in the range of 10,000 units. She was operated upon and given six cycles of chemotherapy. She recovered from her disease and her marker was also within normal range. After one year, the CA 125 began rising and she presented to us with an increased titre of 400 units. There were signs of recurrence, and she opted for DC (DENVAX) therapy in June 2005. She has completed three years of receiving DENVAX. She is free of disease, proven both clinically and by radiological examinations. Her CA 125 marker is also stable for the last three years.We have done series of ovarian cancer patients and the presentation is available in publications section of our webpages.
Know about our latest advancements and how they are leaving an impact on society